NEWS HIGHLIGHTS
Published Studies Related to Oravig (Miconazole)
Efficacy and tolerability of sertaconazole nitrate 2% cream vs. miconazole in patients with cutaneous dermatophytosis. [2011.05]
Sertaconazole is a new antifungal agent. To compare the efficacy and tolerability of sertaconazole and miconazole cream in cutaneous dermatophytosis, this prospective, randomized, multicentric comparative, phase 4 study was undertaken in 260 patients with cutaneous dermatophytosis after approvals from Institutional Ethics Committees...
Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. [2011.03]
Our aim was to assess the effect of miconazole oral gel on the pharmacokinetics of oral oxycodone. In an open crossover study with two phases, 12 healthy volunteers took a single oral dose of 10 mg of immediate-release oxycodone with or without thrice-daily 85-mg miconazole oral gel treatment... Miconazole oral gel produces a rather strong inhibitory effect on CYP2D6, which deserves further study.
Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad(R) efficacy and safety (SMiLES). [2010.07]
BACKGROUND: Oropharyngeal candidiasis (OPC) is the most common opportunistic infection among persons infected with human immunodeficiency virus (HIV). Once-daily miconazole 50 mg buccal tablet (MBT) is a novel delivery system using an extended-spectrum azole with potent in vitro activity against many Candida species, including some that may be resistant to other azoles... CONCLUSIONS: In this large trial, once-daily MBT was shown to be noninferior to CT 5 times daily in the treatment of OPC in HIV-positive patients. MBT offers an effective, safe, and well-tolerated topical treatment option for OPC administered as a convenient once-daily dose.
Antimicrobial central venous catheters in oncology: efficacy of a rifampicin-miconazole-releasing catheter. [2010.04]
CONCLUSION: Immunocompromized patients suffering from cancer, transplantation, and dialysis patients with a long-term vascular access may mostly benefit from rifampicin-miconazole-releasing catheters.
Randomized, comparative, double-blind, double-dummy, multicenter trial of
miconazole buccal tablet and clotrimazole troches for the treatment of
oropharyngeal candidiasis: study of miconazole Lauriad® efficacy and safety
(SMiLES). [2010]
species, including some that may be resistant to other azoles... CONCLUSIONS: In this large trial, once-daily MBT was shown to be noninferior to
Clinical Trials Related to Oravig (Miconazole)
Efficacy of Slow Release Clotrimazole Varnish Treating Denture Stomatitis Comparing to Traditional Treatment of Troches [Not yet recruiting]
Background: Oral candidiasis is most frequently found among the elderly .It is accompanied
with oral pain, irritation, burning sensation. In addition, the altered taste sensation may
cause nutrition compromise, which may affect ones diet. Management of superficial oral
Candida is usually achieved by treatment with clotrimazole, a fungi static drug which is
given five times per day with instruction to slowly suck on it with out the dentures.
Working hypothesis and aims: Management of oral candidiasis is feasible. The major
disadvantage of the mode of action now days is the substantively of the drug in the oral
cavity and patient compliance. A sustained release varnish which is easily applied on the
dentures, which also release the anti fungal drug for at least a day, may overcome some of
the pit falls of the treatment applied today.
Based on our past experience, in developing local sustained release varnishes for dental
use, we anticipate that we can also formulate a special anti fungal sustained release
varnish which will fit the special and unique needs of the elderly population.
Methods: Sustained release varnish will be developed in our laboratory. The kinetics of
release (using HPLC) and antifungal activity (Bioassays) will be examined in vitro. The
formulation showing the optimal results will be tested on human subjects with oral
candidiasis. The efficacy of the varnish will be examined clinically (reduction in
symptoms), microbiology (reduction of oral fungal), pharmaceutically (release kinetics in
vivo).
Expected results: The clinical out come of one time varnish application will be improved
compared to the five times application of lozenges (used today). The severity of the
disease should decrease and the healing period should be shorten drastically.
Importance: This is a novel pharmaceutical development of a local application of a dental
varnish designed specially to the elderly population
Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women [Recruiting]
This research study is about vaginal infections such as bacterial vaginosis, yeast
infections, and trichomoniasis. Usually, these infections can be treated with medication,
but sometimes they come back after treatment. Researchers want to know if using vaginal
suppositories can decrease the risk of vaginal infections. Participants will include 234
women who are sexually active (greater than or equal to 4 episodes of sex with men during
the past month), HIV-negative, 18 to 45 years old, with bacterial infection [vaginosis
and/or vulvovaginal candidiasis (VVC) and/or Trichomonas vaginalis] detected by laboratory
testing at a screening visit. Women will receive vaginal suppositories containing drug or
inactive ingredients (placebo). Participation in the study will be about 12 months. Study
procedures include: urine and blood tests, physical exams, and questionnaires.
Clinical Trial of Hydroquinone Versus Miconazol in Melasma [Recruiting]
Melasma is an acquired discoloration of the skin characterized by brown colour changes
commonly on the face. The duration of this double-blind clinical trial will be 12 weeks. The
control group will receive treatment with topical Hydroquinone (4%), and the other group
topical miconazole. Miconazol has antimelanotic properties and can be used as treatment for
melasma patients. The estimated number of subjects to be recruited and randomized for the
study is at least 30. The purpose of this study is determine if there is a difference in
the effectiveness of these two agents. Melasma Area and Severity Index (MASI) score will be
assessed at the beginning of the study and at weeks 4, 8, and 12. Photographs, colorimetry
and histological assessment will be also evaluated. Occurrence of adverse effects will also
be recorded.
Effectiveness of 3% Boric Acid in 70% Alcohol Versus 1% Clotrimazole Solution in Otomycosis Patients [Recruiting]
Otomycosis is a superficial fungal infection of the external ear canal. Patients should be
treated with cleaning fungal debris combined with topical antifungal agent. There is wide
range of topical antifungal agents. However, there is still no consensus of the most
effective topical antifungal agents in treatment otomycosis is still lacking.
According to Thai National List of essential medicines for topical antifugal agents are:
- acetic acid (2% in aqueous and 2% in 70% isopropyl alcohol)
- boric acid (3% in isopropyl alcohol)
- gentian violet
- clotrimazole ear drop. But from literature review, there is no comparative study
between boric acid and clotrimazole solution before.
Objective is to compare the clinical effectiveness and adverse events of 1% clotrimazole
solution versus 3% boric acid in 70% alcohol for the treatment of otomycosis.
Antifungal Locks to Treat Fungal-Related Central Line Infections [Recruiting]
The purpose of this study is to evaluate the usefulness of antifungal lock therapy with
liposomal amphotericin B (Ambisome), in combination with systemic antifungal(s), in patients
with catheter-related blood stream infections with fungal organisms, whose catheter has not
been removed because of the continuing critical need for central line access. The primary
group of potential patients will be those with intestinal insufficiency, including post-op
small bowel transplant recipients.
The recommendation of the Infectious Disease Society of America is to remove all catheters
with fungal infections and treat systemically for 14 days after the last positive culture.
However, in certain intestinal failure patients, removal of an infected line might
significantly reduce or eliminate intravenous (IV) access and create a life threatening
situation. Thus, the investigators' aim is to determine the usefulness of antifungal lock
therapy in intestinal failure patients whose catheter has not been removed. The
investigators' hope is to salvage central line catheters rather than to remove them.
|
